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Hypofractionation for prostate cancer and PROs
In the non-inferiority CHHiP trial, 3216 patients 
underwent intensity-modulated radiotherapy for 
localised prostate cancer. The study compared 
conventional fractionation at a dose of 74 Gy in 
37 fractions, previously assessed in the RT01 trial,1 with 
two moderately hypofractionated schedules: 60 Gy in 
20 fractions and 57 Gy in 19 fractions, with fractions of 
3 Gy per day. The quality-of-life (QoL) substudy by Anna 
Wilkins and colleagues2 describes the patient-reported 
outcomes (PROs) of 2100 patients, which were assessed 
with several QoL instruments. The incidence of bowel 
and urinary symptoms were low and similar in the 
control and hypofractionated groups up to 24 months 
of follow-up, with no diﬀ erences with respect to time-
to-event analysis of small or worse overall bowel, 
urinary, and sexual bother.
Intensity-modulated radiotherapy is a high-precision 
external beam radiotherapy approach that is regarded 
as the gold standard for the treatment of localised 
prostate cancer.3 Intensity modulation has oﬀ ered the 
opportunity to launch phase 3 randomised trials to 
investigate whether overall treatment times can be 
reduced by increasing the dose per fraction, without 
increasing acute and late toxic eﬀ ects, and while 
maintaining quality of life for patients. Prostate cancer 
has a low cell renewal rate;4 its low α/β ratio, about 1·4,5 
describes the association between the delivered dose 
and the clinical response. Such a ratio enables radiation 
oncologists to choose a hypofractionation regimen that 
is biologically equivalent to a conventional fractionation 
treatment with 2 Gy per fraction. Hence, prostate cancer 
is expected to have a greater sensitivity to the higher 
dose per fraction (2·5–4·0 Gy) oﬀ ered by moderate 
hypofractionation. 
An interim analysis of the CHHiP trial6 that included 
457 patients reported no diﬀ erence between 
treatment groups in the proportion of patients with 
grade 2 or higher gastrointestinal or bladder toxic 
eﬀ ects. The trial had a comprehensive methodology 
and strict radiotherapy quality assurance with 
appropriate dose constraints, and is the ﬁ rst to report 
quality of life with PROs in such a large population. 
However, a few points should be raised. The inclusion 
of high-risk prostate cancer is controversial because 
pelvic lymph node irradiation is needed for such 
cases, which might be harmful if delivered by 
hypofractionation because of the radiosensitivity of 
the small bowel. The dose used in the control group 
(74 Gy) would usually be regarded as an intermediate 
dose: a high dose would typically fall in the range 
of 78–80 Gy. High-risk prostate cancer requires a 
longer duration of androgen deprivation therapy 
compared with lower risk forms: 2–3 years rather 
than 3–6 months.7 As mentioned by the authors,2 
radiotherapy-related toxic eﬀ ects, particularly faecal 
incontinence, rectal bleeding, and use of urinary pads, 
were likely to be underestimated because of the use of 
diﬀ erent QoL instruments. 
The results of the QoL substudy support the 
superiority of intensity-modulated radiotherapy 
compared with conformal external beam radiotherapy. 
In both the CHHiP and RT01 trials, the intensity-
modulated schedules show signiﬁ cantly fewer adverse 
gastrointestinal events compared with the 74 Gy 
schedules.8 Other phase 3 randomised trials have 
investigated moderate hypofractionation for localised 
prostate cancer, but these were done with diﬀ erent 
techniques and sometimes had no comprehensive 
health-related QoL assessments: a systematic review9 
of these studies supports the safety of moderate 
hypofractionation but also emphasises the scarcity of 
data about long-term eﬃ  cacy. In oncology, treatment 
choices are based on eﬃ  cacy, toxic eﬀ ects, patient 
quality of life, and ﬁ nally treatment costs (once the 
other parameters have been met). Before moderate 
hypofractionation can be recommended in daily 
practice for low-risk and intermediate-risk prostate 
cancer,10 mature data from the CHHiP trial are needed 
(showing the non-inferiority of hypofractionated 
regimens and 5-year urinary, bowel, and sexual 
adverse event data), as are results from trials such as 
the Radiation Therapy Oncology Group 0415 trial and 
the PROFIT trial from the Ontario Clinical Oncology 
Group. If moderate hypofractionation is non-inferior 
to fractionated intensity-modulated radiotherapy, 
this approach could be more convenient for patients, 
improve access to treatment, and might reduce 
treatments costs. 
In the near future, the use of hypofractionation 
will face other challenges, including whether 
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In The Lancet Oncology, Francesca Gay and colleagues report 
ﬁ ndings of an international, multicentre randomised study 
in patients with newly diagnosed multiple myeloma.1 
Lenalidomide and dexamethasone were administered as 
induction treatment, followed by randomisation to either 
cyclophosphamide, lenalido mide, and dexamethasone 
or high-dose melphalan and autologous stem-cell 
transplantation (ASCT) as consolidation, and either 
lenalidomide alone or lenalidomide and prednisone 
as maintenance. This work builds on a previous study 
in which lenalidomide induction was followed by 
randomisation to either oral melphalan, lenalidomide, 
and prednisone or tandem high-dose melphalan and 
ASCT.2 In that report, better progression-free survival and 
overall survival were reported for ASCT compared with 
chemotherapy. A second randomisation to lenalidomide 
maintenance versus placebo showed better progression-
free survival for patients assigned lenalidomide.  
Gay and colleagues reported that median progression-
free survival was signiﬁ cantly longer for melphalan 
and ASCT compared with cyclophosphamide, 
lenalido mide, and dexamethasone (43·3 months [95% 
CI 33·2–52·2] vs 28·6 months [20·6–36·7]; hazard ratio 
[HR] for the ﬁ rst 24 months 2·51, 95% CI 1·60–3·94; 
p<0·0001). 4-year overall survival was signiﬁ cantly 
better for melphalan and ASCT compared with 
cyclophosphamide, lenalidomide, and dexamethasone 
(86% [95% CI 79–92] vs 73% [65–82]; HR 2·40, 
95% CI 1·32–4·38; p=0·004). The report reinforces 
the superiority of transplantation over continued 
chemotherapy for treatment of patients with newly 
diagnosed multiple myeloma. This superiority persists 
in the era of novel agents used for induction and 
salvage. Of note, only 53 (43%) of 124 patients assigned 
cyclophosphamide, lenalidomide, and dexamethasone 
received salvage ASCT after progressive disease, 
showing that salvage ASCT after relapse is not always 
feasible. The addition of prednisone to lenalidomide 
maintenance did not signiﬁ cantly improve progression-
free survival or overall survival. Thus, other agents need 
to be investigated for maintaining response after ASCT, 
as has been seen with single-agent lenalidomide.  
moderate hypofractionation can be combined 
with brachytherapy, and the advent of extreme 
hypofractionation (5–10 Gy in four to seven fractions). 
Such approaches will have to be managed within 
the framework of clinical research, with careful 
estimation of each patient’s comorbidities and their 
gastrointestinal and genitourinary function, as 
assessed with the International Prostate Symptom 
Score and uroﬂ owmetry recordings. Treatment 
delivery can be improved with image-guided 
radiotherapy, with strict quality assurance to avoid 
compromising a potential salvage treatment in case of 
local relapse.  
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